Scientific Program Committee

CROI 2008 Session 28
c Tuesday, 2-3 pm; Room 312
CME
Session 27–Poster Discussion
(see Session 133 on Wednesday for corresponding Poster Abstracts)
Risk Factors for Lost-to-Follow-up in Resourcelimited
Settings
Discussants:
Wafaa El-Sadr, Harlem Hosp Ctr, Columbia Univ, New York, NY, US
Charles Gilks, World Hlth Org, Geneva, Switzerland
838 Characteristics of Facilities and Programs Delivering HIV
Care and Treatment Services Are Associated with Loss to
Follow-up Rates in Programs from 7 Sub-Saharan African
Countries
Denis Nash* 1 , C Korves 1 , S Saito 1 , S Sherman 1 , B Elul 1 , D Hoos 1 ,
V Mugisha 2 , M Sheriff 3 , W El Sadr 1 , and Intl Ctr for AIDS Care and
Treatment Prgms (ICAP)
1 Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US; 2 Columbia
Univ, Intl Ctr for AIDS Care and Treatment Prgms, Kigali, Rwanda; and
3 Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms, Nairobi,
Kenya
839 Loss to Care and Death before ART: Patients Eligible for
Treatment Who Do Not Make It in Durban, South Africa
Ingrid Bassett* 1,2,3 , B Wang 1 , S Chetty 4 , J Giddy 4 , Z Lu 1 , E Losina 2,3,5 ,
R Walensky 1,2,3,6 , and K Freedberg 1,3,5,6
1 Massachusetts Gen Hosp, Boston, US; 2 Brigham and Women’s Hosp,
Boston, MA, US; 3 Harvard Med Sch, Boston, MA, US; 4 McCord Hosp,
Durban, South Africa; 5 Boston Univ Sch of Publ Hlth, MA, US; and
6 Harvard Sch of Publ Hlth, Boston, MA, US
840 Losses to Follow-up in a Large ART Program in Uganda
A Muwanga, Philippa Easterbrook*, P Schaefer, M Wandera, D Okello,
B Castelnuovo, M Kamya, and A Kambugu
Infectious Disease Inst, Kampala, Uganda
841 Loss to Follow-up in Community Clinics in South Africa:
Role of CD4 Count, Gender, and Pregnancy
Bingxia Wang* 1,2 , E Losina 1,3,4 , R Stark 5 , A Munro 5 , R Walensky 1,2,3 ,
M Wilke 5 , D Martin 5 , Z Lu 1 , K Freedberg 1,2,4,6 , and R Wood 7
1 Massachusetts Gen Hosp, Boston, US; 2 Harvard Med Sch, Boston, MA,
US; 3 Brigham and Women’s Hosp, Boston, MA, US; 4 Boston Univ Sch of
Publ Hlth, MA, US; 5 South Africa Catholic Relief Svcs; 6 Harvard Sch of
Publ Hlth, Boston, MA, US; and 7 Univ of Cape Town, South Africa
842 What Becomes of the Defaulters? A Sampling-based
Approach to Determine Outcomes of Patients Who Become
Lost to Follow-up in ART Scale-up Programs in Africa
Elvin Geng* 1 , D Bangsberg 1 , N Musinguzi 2 , N Emenyonu 1 , M Bwana 2 ,
D Glidden 1 , C Yiannoutsos 3 , S Deeks 1 , J Martin 1 , and East Africa IeDEA
Consortium
1 Univ of California, San Francisco, US; 2 Mbarara Univ of Sci and Tech,
Uganda; and 3 Indiana Univ, Indianapolis, US
c Tuesday, 2-3 pm; Room 302-304
CME
Session 28–Poster Discussion
(see Session 91 on Monday for corresponding Poster Abstracts)
Novel PrEP Agents and Evaluation Strategies
Discussants:
Walid Heneine, CDC, Atlanta, GA, US
Sharon Hillier, Univ of Pittsburgh, Magee-Womens Res Inst, PA, US
556 An Engineered Bi-functional HIV-1 Neutralizing Protein as
a Potential Microbicide
Vadim Villarroel* 1 , L Lagenaur1,2 , and E Berger1 1 2 NIAID, NIH, Bethesda, MD, US and Osel, Inc, Santa Clara, CA, US
557 Better Protection against HIV-1 Infection in vitro with
Candidate Microbicide Compounds in Combination
Susan Schader* 1,2 , B Scarth2 , S Colby-Germinario1 , J Schachter1 ,
J Nuttall3 , M Gotte2 , and M Wainberg1,2 1 2 McGill Univ AIDS Ctr, Lady Davis Inst, Montreal, Canada; McGill
Univ, Montreal, Canada; and 3Intl Partnership for Microbicides, Silver
Spring, MD, US
558 Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal
Transmission of HIV-1 in Humanized BLT Mice
Paul Denton* 1 , J Estes 2 , Z Sun 1 , F Othieno 1 , D Powell 1 , A Haase 2 , and
V Garcia 1
1 Univ of Texas Southwestern Med Ctr, Dallas, US and 2 Univ of
Minnesota, Minneapolis, US
559a Size-fitting of Intravaginal Rings for Macaques and in vitro
Release Kinetics of Zinc Finger Inhibitors
James Smith* 1 , K Malcolm 2 , E Appella 3 , C McConville 2 , M Schito 3 ,
D Woolfson 2 , R Hayashi 3 , N Lanier 1 , R Otten 1 , and S Butera 1
1 CDC, Atlanta, GA, US; 2 Queen’s Univ of Belfast, Sch of Pharmacy,
Northern Ireland; and 3 NCI, NIH, Bethesda, MD, US
559b Safety and Pharmacokinetic Assessment of 28-Day Anti-HIV
Dapivirine Intravaginal Microbicide Rings
Annalene Nel* 1 , S Smythe 1 , K Young 1 , K Malcolm 2 , Z Rosenberg 1 , and
J Romano 1
1 Intl Partnership for Microbicides, Silver Spring, MD, US and 2 Queen’s
Unive, Belfast, Northern Ireland
560 Topical Application of Fully Recombinant RANTES Analogs
Protect Macaques from Vaginal SHIV Transmission
Ronald Veazey* 1 , M Lederman 2 , B Ling 1 , L Green 1 , E Ribka 1 , D Mosier 3 ,
R Offord 4,5 , and O Hartley 4
1 Tulane Natl Primate Res Ctr, Covington, LA, US; 2 Case Western
Reserve Univ, Cleveland, OH, US; 3 Scripps Res Inst, La Jolla, CA, US;
4 Univ of Geneva, Switzerland; and 5 Mintaka Fndn for Med Res, Geneva,
Switzerland
Program 15
Tuesday
February 5 Sessions